This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lupin Expands Branded Play

MUMBAI and BALTIMORE, August 7, 2013 /PRNewswire/ --

Announces Acquisition of Exclusive US Rights to Alinia® for Oral Suspension

Pharmaceutical Major, Lupin Ltd. and its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) announced today that it has signed a strategic licensing agreement with US pharmaceutical company Romark Laboratories, L.C. (Romark) which grants Lupin exclusive rights to promote, distribute and market Alinia® (nitazoxanide) for Oral Suspension in the US.

Alinia® (nitazoxanide) is the first thiazolide approved by the FDA for the treatment of diarrhea caused by Cryptosporidium and Giardia and is the only FDA-approved treatment for Cryptosporidium. Alinia® for Oral Suspension is indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 1 year of age and older. These are the two most common protozoal causes of diarrhea in the developed and developing world.

Use of Alinia® suspension in children is facilitated by relatively simple dosing and administration; a strawberry flavored suspension given twice a day for three days (100mg BID for ages 1 - 3 and 200mg BID for ages 4 - 11).

According to the Centers of Disease Control & Prevention (CDC) it is estimated that there are 1.2 million cases of Giardiasis and 750,000 cases of Cryptosporidiosis in the US annually, although many cases go undiagnosed. Cryptosporidium is one of the most frequent causes of waterborne disease among humans in the United States. Pediatric diarrhea is a major complaint in more than 10% of office visits for children less than 3 years of age, says the American Academy of Pediatrics (AAP). Over 300,000 children under five years of age are hospitalized with gastroenteritis annually. Pediatric diarrhea is often left untreated based on limited treatment options (no other product is indicated for children < 3 years of age).  Older children are sometimes treated with flouroquinolones (e.g., CIPRO), cephalosporins (e.g., SUPRAX) and metronidazole. The cost of care for diarrhea-related illness exceeds USD 2 billion each year according to AAP.

Alinia® for Oral Suspension will not only enable Lupin to strengthen its existing Brand portfolio but also expand its offering specifically, but not limited to the US Pediatrics segment. Key prescribers for Alinia® include pediatricians, pediatric, gastroenterologists and primary care physicians which are strategic customer groups for Lupin, so we are well positioned to capitalize on this opportunity. Lupin's current 160+ strong brands sales force will promote Alinia® for Oral suspension in the US market. The product will be marketed along with Lupin's Suprax® and Antara®.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,239.16 -46.58 -0.25%
S&P 500 2,128.23 -2.59 -0.12%
NASDAQ 5,092.9980 +2.2040 0.04%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs